China Pharma Holdings (CPHI) Total Debt (2010 - 2026)

China Pharma Holdings (CPHI) has reported Total Debt for 17 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Debt fell 12.83% year-over-year to $3.6 million; the trailing twelve-month figure through Jun 2026 stood at $3.6 million (down 12.83% YoY), and the FY2025 full-year result was $3.4 million, down 7.3% from the prior year.
• Total Debt climbed to $3.6 million in Q2 2026 per CPHI's latest filing, from $3.4 million in the prior quarter.
• Across five years, Total Debt topped out at $9.1 million in Q3 2022 and bottomed at $2.8 million in Q3 2024.
• Historically, Total Debt has averaged $4.2 million across 5 years, with a median of $3.7 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Debt surged 471.65% in 2022, then plunged 54.63% in 2023.
• Over 5 years, Total Debt stood at $6.2 million in 2022, then tumbled by 41.04% to $3.7 million in 2023, then advanced by 0.04% to $3.7 million in 2024, then dropped by 7.3% to $3.4 million in 2025, then increased by 5.63% to $3.6 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $3.6 million, $3.4 million, and $3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.